Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.

MLA

Zhou, Taotao, et al. “Case Report: Sustained Complete Remission on Combination Therapy with Olaparib and Pembrolizumab in BRCA2-Mutated and PD-L1-Positive Metastatic Cholangiocarcinoma after Platinum Derivate.” Frontiers in Oncology, vol. 12, July 2022, p. 933943. EBSCOhost, https://doi.org/10.3389/fonc.2022.933943.

APA

Zhou, T., Mahn, R., Möhring, C., Sadeghlar, F., Meyer, C., Toma, M., Kreppel, B., Essler, M., Glowka, T., Matthaei, H., Kalff, J. C., Strassburg, C. P., & Gonzalez-Carmona, M. A. (2022). Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Frontiers in Oncology, 12, 933943. https://doi.org/10.3389/fonc.2022.933943

Chicago

Zhou, Taotao, Robert Mahn, Christian Möhring, Farsaneh Sadeghlar, Carsten Meyer, Marieta Toma, Barbara Kreppel, et al. 2022. “Case Report: Sustained Complete Remission on Combination Therapy with Olaparib and Pembrolizumab in BRCA2-Mutated and PD-L1-Positive Metastatic Cholangiocarcinoma after Platinum Derivate.” Frontiers in Oncology 12 (July): 933943. doi:10.3389/fonc.2022.933943.